Stock Analysis Report

Executive Summary

Orion Oyj engages in the development and manufacture of pharmaceuticals and active pharmaceutical ingredients (APIs) worldwide.


Earnings are forecast to grow 7.91% per year

Earnings grew by 1.5% over the past year

Risk Analysis

Dividend of 3.89% is not well covered by earnings or forecast to be in the next 3 years

Snowflake Analysis

Flawless balance sheet with proven track record.

Similar Companies

Share Price & News

How has Orion Oyj's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: ORNBV has not had significant price volatility in the past 3 months.

Market Performance

7 Day Return




FI Pharmaceuticals


FI Market

1 Year Return




FI Pharmaceuticals


FI Market

Return vs Industry: ORNBV exceeded the Finnish Pharmaceuticals industry which returned 17.4% over the past year.

Return vs Market: ORNBV exceeded the Finnish Market which returned 10.1% over the past year.

Shareholder returns

7 Day0.2%-0.01%-2.8%
30 Day-11.8%1.5%0.6%
90 Day-2.0%9.7%8.1%
1 Year37.2%31.2%25.2%18.5%14.6%9.6%
3 Year-6.0%-17.4%40.0%24.2%32.1%16.3%
5 Year65.9%33.4%39.2%15.6%44.8%17.5%

Price Volatility Vs. Market

How volatile is Orion Oyj's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is Orion Oyj undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: ORNBV (€38.58) is trading above our estimate of fair value (€37.18)

Significantly Below Fair Value: ORNBV is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: ORNBV is poor value based on its PE Ratio (27.1x) compared to the Pharmaceuticals industry average (25.8x).

PE vs Market: ORNBV is poor value based on its PE Ratio (27.1x) compared to the Finnish market (21.6x).

Price to Earnings Growth Ratio

PEG Ratio: ORNBV is poor value based on its PEG Ratio (3.4x)

Price to Book Ratio

PB vs Industry: ORNBV is overvalued based on its PB Ratio (7x) compared to the XE Pharmaceuticals industry average (3.1x).

Next Steps

Future Growth

How is Orion Oyj forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORNBV's forecast earnings growth (7.9% per year) is above the savings rate (-0.1%).

Earnings vs Market: ORNBV's earnings (7.9% per year) are forecast to grow slower than the Finnish market (10% per year).

High Growth Earnings: ORNBV's earnings are forecast to grow, but not significantly.

Revenue vs Market: ORNBV's revenue (3.5% per year) is forecast to grow faster than the Finnish market (-0% per year).

High Growth Revenue: ORNBV's revenue (3.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ORNBV's Return on Equity is forecast to be high in 3 years time (29.6%)

Next Steps

Past Performance

How has Orion Oyj performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ORNBV has high quality earnings.

Growing Profit Margin: ORNBV's current net profit margins (19.1%) are lower than last year (20.2%).

Past Earnings Growth Analysis

Earnings Trend: ORNBV's earnings have declined by -2.6% per year over the past 5 years.

Accelerating Growth: ORNBV's earnings growth over the past year (1.5%) exceeds its 5-year average (-2.6% per year).

Earnings vs Industry: ORNBV earnings growth over the past year (1.5%) exceeded the Pharmaceuticals industry -5%.

Return on Equity

High ROE: ORNBV's Return on Equity (25.7%) is considered high.

Return on Assets

Return on Capital Employed

Next Steps

Financial Health

How is Orion Oyj's financial position?

Financial Position Analysis

Short Term Liabilities: ORNBV's short term assets (€600.1M) exceed its short term liabilities (€187.5M).

Long Term Liabilities: ORNBV's short term assets (€600.1M) exceed its long term liabilities (€68.8M).

Debt to Equity History and Analysis

Debt Level: ORNBV's debt to equity ratio (0.3%) is considered satisfactory.

Reducing Debt: ORNBV's debt to equity ratio has reduced from 45.3% to 0.3% over the past 5 years.

Debt Coverage: ORNBV's debt is well covered by operating cash flow (11773.9%).

Interest Coverage: ORNBV's interest payments on its debt are well covered by EBIT (133.1x coverage).

Balance Sheet

Inventory Level: ORNBV has a high level of physical assets or inventory.

Debt Coverage by Assets: ORNBV's debt is covered by short term assets (assets are 260.9x debt).

Next Steps


What is Orion Oyj's current dividend yield, its reliability and sustainability?


Current Dividend Yield

Upcoming Dividend Payment

Purchase Orion Oyj before the 'Buy Limit' to receive their next dividend payment.

Dividend Yield vs Market


Current dividend yield vs market & industry

Notable Dividend: ORNBV's dividend (3.89%) is higher than the bottom 25% of dividend payers in the Finnish market (2.07%).

High Dividend: ORNBV's dividend (3.89%) is low compared to the top 25% of dividend payers in the Finnish market (4.47%).

Stability and Growth of Payments

Stable Dividend: ORNBV's dividends per share have been stable in the past 10 years.

Growing Dividend: ORNBV's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (105.2%), ORNBV's dividend payments are not well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: ORNBV's dividends in 3 years are not forecast to be well covered by earnings (97.9% payout ratio).

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Timo Lappalainen (57yo)





Mr. Timo Lappalainen, M.Sc. (Ind. Eng.), has been the Chief Executive Officer and President of Orion Oyj (Formerly, Orion Corporation) since January 2008. Mr. Lappalainen has been the Chairman of the Execu ...

CEO Compensation Analysis

Compensation vs Market: Timo's total compensation ($USD1.46M) is about average for companies of similar size in the Finnish market ($USD1.16M).

Compensation vs Earnings: Timo's compensation has been consistent with company performance over the past year.

Leadership Team

Timo Lappalainen
CEO, President & Chairman of the Executive Management Board12.1yrs€1.35m0.075% 4.1m
Jari Karlson
CFO, Senior VP of Animal Health & Member of the Executive Management Board17.5yrsno data0.020% 1.1m
Olli Huotari
Senior VP of Corporate Functions0yrsno data0.039% 2.1m
Markku Huhta-Koivisto
Senior VP of Growth Projects & Member of Executive Management Board0yrsno data0.019% 1.1m
Satu Ahomäki
Senior VP of Commercial Operations and Member of the Executive Management Board12.1yrsno data0.019% 1.0m
Liisa Hurme
Senior VP of Supply Chain & Member of the Executive Management Board0yrsno data0.019% 1.0m
Virve Laitinen
Senior VP of Specialty Products & Member of Executive Management Board8.1yrsno data0.014% 743.0k
Marko Torppala
Employee Representative Executive Management Board0yrsno datano data
Christer Nordstedt
Senior VP of Research & Development and Member of Executive Management Board3yrsno data0.0030% 161.1k
Tuukka Hirvonen
Investor Relations & Financial Communications Officer0yrsno datano data


Average Tenure


Average Age

Experienced Management: ORNBV's management team is seasoned and experienced (12.1 years average tenure).

Board Members

Heikki Westerlund
Chairman2.9yrs€117.54k0.0088% 479.5k
Mikael Silvennoinen
Independent Director5.9yrs€62.67k0.0039% 212.8k
Timo Maasilta
Vice Chairman3.9yrs€79.65k0.019% 1.0m
Ari Lehtoranta
Independent Director2.9yrs€57.27k0.00072% 39.2k
Pia Kalsta
Independent Director0.9yrsno datano data
Eija Ronkainen
Independent Director3.9yrs€57.27k0.0078% 426.7k
Hilpi Rautelin
Independent Director2.9yrs€56.67k0.0027% 147.5k


Average Tenure


Average Age

Experienced Board: ORNBV's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Orion Oyj's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Orion Oyj
  • Ticker: ORNBV
  • Exchange: HLSE
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €5.443b
  • Shares outstanding: 140.49m
  • Website: https://www.orion.fi

Number of Employees


  • Orion Oyj
  • Orionintie 1A
  • Espoo
  • Uusimaa
  • 2200
  • Finland


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORNAVHLSE (OMX Nordic Exchange Helsinki)Class A SharesFIEURJul 2006
ORNBVHLSE (OMX Nordic Exchange Helsinki)YesClass B SharesFIEURJul 2006
OFKDB (Deutsche Boerse AG)YesClass B SharesDEEURJul 2006
0M2NLSE (London Stock Exchange)Class A SharesGBEURJul 2006
0M2OLSE (London Stock Exchange)YesClass B SharesGBEURJul 2006
ORIN.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDJul 2006
ORNBVHBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBEURJul 2006
ORNAVHBATS-CHIXE (BATS 'Chi-X Europe')Class A SharesGBEURJul 2006


Orion Oyj engages in the development and manufacture of pharmaceuticals and active pharmaceutical ingredients (APIs) worldwide. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson’s disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as offers contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has research collaboration with Fifth Corner Inc. to seek solutions to improve the quality of life of prostate cancer patients. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics, and laboratories. Orion Oyj is headquartered in Espoo, Finland. 

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 21:15
End of Day Share Price2020/02/19 00:00
Annual Earnings2019/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.